[removed]Silenor[/removed] (doxepin), indicated for the treatment of insomnia characterized by difficulty with sleep maintenance, is now commercially available by prescription in the United States. Somaxon, maker of the insomnia treatment, has implemented a wholesale and retail stocking program to disseminate Silenor 3 mg and 6 mg dose packs to pharmacies across the United States.

“The commercial availability of Silenor, the first and only prescription product approved for the treatment of sleep maintenance insomnia that is not a controlled substance, is an important milestone for Somaxon and marks the completion of our product launch preparations,” said Richard W. Pascoe, Somaxon’s president and CEO. “We look forward to promoting this highly differentiated product to health care providers alongside our co-promotion partner, Procter & Gamble. Our combined sales teams will begin full-scale, field-based promotion of the product on September 20, 2010, targeting approximately 35,000 physicians and 25,000 pharmacies across the US.”

“In conjunction with the deployment of our field-based promotion to health care providers, we will launch a comprehensive marketing program that will utilize web-based initiatives and will be directed at both physicians not called on directly by our sales force as well as patients suffering from sleep maintenance insomnia,” continued Pascoe. “This campaign will highlight the traits that we believe will position Silenor for success in the insomnia market—the ability to treat sleep maintenance insomnia into the final hours of the night without meaningful next-day residual effects and without abuse potential.”

Comment on this treatment at Sleep Review‘s Facebook page.